---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-006194"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2023-01-24T23:59:59+00:00"
generated_at: "2026-06-20T10:38:38.315044+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Precigen reports positive Phase 1 PRGN-2012 data: 50% complete response in RRP patients

## Summary
- 50% of RRP patients at Dose Level 2 achieved Complete Response, requiring no post-treatment surgeries.
- Median annual RRP surgeries dropped from 6.5 pre-treatment to 0.5 post-treatment at Dose Level 2.
- PRGN-2012 well-tolerated with no dose-limiting toxicities and no treatment-related Grade ≥3 adverse events.
- Preliminary cash, equivalents, and investments totaled ~$56M as of Dec 31, 2022; restricted cash ~$43.7M.
- Phase 2 study enrolling; 32 patients enrolled at Dose Level 2 to date; FDA discussions advancing for regulatory strategy.

## SEC filing metadata
- accession: 0001104659-23-006194
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2023-01-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000110465923006194/0001104659-23-006194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000110465923006194/tm234280d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-006194
- JSON: https://secwatch.observer/filing/0001104659-23-006194.json
- Plain text: https://secwatch.observer/filing/0001104659-23-006194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.